Advertisement
Singapore markets closed
  • Straits Times Index

    3,144.76
    -38.85 (-1.22%)
     
  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     
  • Dow

    37,735.11
    -248.13 (-0.65%)
     
  • Nasdaq

    15,885.02
    -290.08 (-1.79%)
     
  • Bitcoin USD

    63,243.61
    -3,454.52 (-5.18%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,848.62
    -116.91 (-1.47%)
     
  • Gold

    2,386.40
    +3.40 (+0.14%)
     
  • Crude Oil

    85.04
    -0.37 (-0.43%)
     
  • 10-Yr Bond

    4.6280
    0.0000 (0.00%)
     
  • Nikkei

    38,471.20
    -761.60 (-1.94%)
     
  • Hang Seng

    16,248.97
    -351.49 (-2.12%)
     
  • FTSE Bursa Malaysia

    1,535.00
    -7.53 (-0.49%)
     
  • Jakarta Composite Index

    7,164.81
    -122.07 (-1.68%)
     
  • PSE Index

    6,404.97
    -157.46 (-2.40%)
     

Nektar’s NKTR-181 Expected to Transform Chronic Pain Market

Nektar Therapeutics (NKTR) plans to submit an NDA (New Drug Application) with the FDA (U.S. Food & Drug Administration) for late-stage chronic pain drug NKTR-118 by April 2018.